Publications

23-04-2025

Abstract No: 0556, ISNCON Conference 2014 Efficacy and Safety of Indigenously Developed Darbepoetin Alfa in Dialysis Patients - A Randomised Study

31-03-2025

Abstract No: 0556, ISNCON Conference 2014 A Randomized, Comparative, Open-label Clinical Trial of Darbepoetin Alfa Biosimilar for the Treatment of Anaemia in Pre-Dialysis Chronic Kidney Disease Patients

21-12-2024

Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study

05-11-2024

Efficacy and Safety of Rituximab Biosimilar (DRL_RI) Versus Mabthera in Low Tumor Burden Follicular Lymphoma: The Flinter Study

17-01-2024

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial

12-10-2023

Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study

02-10-2023

Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era

04-11-2022

Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamics evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

25-03-2022

Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience

31-08-2021

A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin (EU) in healthy adult males